A precision medicine company

Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax in 2004, Dr. Salamone was Vice President of Research and Development at Roche Diagnostics where he was responsible for North American research and development efforts for the Laboratory Systems Division. During his 17-year tenure at Roche, Dr. Salamone’s efforts resulted in the launch of seven major reagent product lines, comprised of more than 70 FDA-approved products and more than 200 instrument applications. At Saladax Dr. Salamone’s group has developed proprietary positions in the field of oncology and psychiatry drug management. These assays address unmet medical needs in providing precision treatment. Dr. Salamone is recognized globally in the field of drug monitoring, having authored more than 100 publications, including articles, textbook chapters, books, and is also the holder of 41 issued US patents and the corresponding international patents. He has received numerous awards and in 2016 he was inducted into the prestige’s New Jersey Inventors Hall of Fame. Dr. Salamone earned two bachelor’s degrees from Villanova University, a master’s and a Ph.D degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at Oxford University.

Dr. Baburina worked at Roche Diagnostics, where she led the Process Optimization and Transfer group for multiple assay technologies and was responsible for process validation, product support and process improvements, as well as customer complaint investigations and resolutions. She has extensive experience in research and development, working with customers and collaborative business partners in the U.S. and Europe. Dr. Baburina earned a bachelor’s degree from Moscow State University and a Ph.D degree from Rutgers University. Her post-doctoral research at St. Jude Children’s Research Hospital focused on phospholipid-based antineoplastic agents.

Ms. Werner has over 29 years’ experience in the diagnostic industry. Prior to joining Saladax, Ms. Werner worked at Ortho Clinical Diagnostics, where she developed and implemented regulatory strategies for the global licensing of in vitro diagnostic devices. She has extensive Pre-Market Submission and approval experience and demonstrated success at building productive relationships with the US FDA. Prior to that, Ms. Werner researched and developed nucleic acid based diagnostic tests for infectious diseases. Ms. Werner earned a bachelor’s degree from the State University of New York at Buffalo. She holds ten US patents related to her work in diagnostics.

Ms. Courtney has over 25 years of experience in research and development of in vitro diagnostic products. Before joining Saladax she spent 15 years in the Roche Diagnostics Research and Development Department, working with Dr. Salamone. She was instrumental in developing many of the technologies and procedures that were used in the successfully launched drug monitoring product lines. While at Roche, Ms. Courtney developed her international experience working in Basel, Switzerland, where she was responsible for system integration of drug monitoring products on the first medium-throughput consolidated Roche instrument. Ms. Courtney received her bachelor’s degree from Beloit College where she graduated first in her class of chemistry and attended Cornell University as a graduate student.

Mr. Happ has been on the commercial side of the Diagnostic Industry for more than 27 years. His career has focused on the addiction, behavioral health, and mental health fields. In 2015 the New York State Council of Probation Administrators gave him a Lifetime Achievement Award. Mr. Happ has a demonstrable and successful track record of implementing new products at such companies as Roche Diagnostics, Varian/Aglient and Abbott Laboratories. Mr. Happ’s strength is as a relationship builder. He is consistently recognized by customers and decision makers as a true partner in providing customer focused solutions. Mr. Happ earned a B.S. degree in criminal justice from The College of New Jersey and a M.S. in Administration of Justice from Shippensburg University, PA.

Rich served as the CFO of Follett Corporation from 2010 to 2018 and was instrumental in the strong growth of Follett Corporation. Rich was responsible for the company’s finance functions, including financial analysis, financial plans and controls, strategic planning, risk management, tax management, bank relations, and information technology. Rich also played a key role in the 2016 sale of Follett to Middeleby Corporation (NASDAQ: MIDD).

From 1996 until 2000, Rich was CFO of STC Technologies, the predecessor company to Orasure Technologies (NASDAQ: OSUR). In 2000, STC merged with Epitope and formed Orasure Technologies, a world leader in saliva-based infectious disease testing, in a transaction valued at approximately $260M for STC’s shareholders. Following the merger, Rich also served as vice president of Finance of Orasure Technologies, Inc., from 2001 until 2005.

Rich currently serves on the advisory board of Originate Ventures, a Bethlehem-based private equity firm focused on early stage companies.

He graduated from Lehigh University in 1993 with a Masters of Business Administration and from Moravian College in 1985 with a Bachelor of Arts degree in Accounting and a minor in Mathematics.

DeWayne is a change agent who has served as interim manager or advisor on over 20 companies. In his nearly 10 years as a change agent, DeWayne has served as an advisor, board member, interim manager, investor and operator at organizations ranging in size from pre-revenue startups to $100M+ organizations. DeWayne has several successful turnarounds to his credit and is an advisor to several investors and Venture Capital Funds.